Pancreatic Cancer-Derived Exosomes Cause Paraneoplastic β-cell Dysfunction

Area of Science:

• Endocrinology
• Oncology
• Cell Biology

Background:

• Pancreatic cancer is strongly associated with new-onset diabetes.
• Adrenomedullin is a suspected mediator of pancreatic beta-cell dysfunction in cancer patients.
• The mechanism by which pancreatic cancer affects remote beta cells remains unclear.

Purpose of the Study:

• To investigate if pancreatic cancer-derived adrenomedullin is transported to beta cells via exosomes.
• To determine if these exosomes impair beta-cell function and insulin secretion.

Main Methods:

• Characterization of exosomes from pancreatic cancer cell lines and patient blood.
• Western blot analysis for adrenomedullin presence in exosomes.
• Assessment of exosome effects on insulin secretion from beta cells (INS-1 and human islets).
• Investigation of exosome internalization mechanisms and adrenomedullin receptor interactions.
• Analysis of endoplasmic reticulum stress and reactive oxygen/nitrogen species generation in beta cells.

Main Results:

• Pancreatic cancer cells secrete adrenomedullin- and CA19-9-containing exosomes.
• These exosomes are internalized by beta cells and inhibit insulin secretion.
• Adrenomedullin on exosomes binds to beta-cell receptors, mediating the inhibitory effect.
• Exosomes induce endoplasmic reticulum stress and increase reactive oxygen/nitrogen species in beta cells.

Conclusions:

• Pancreatic cancer causes paraneoplastic beta-cell dysfunction via circulating adrenomedullin-positive exosomes.
• These exosomes inhibit insulin secretion by inducing endoplasmic reticulum stress and impairing the unfolded protein response.
• This pathway explains how pancreatic cancer contributes to diabetes in affected patients.